The US Food and Drug Administration (FDA) has expanded the emergency use authorization for Pfizer-BioNTech Covid-19 vaccination boosters to include youngsters aged 12 to 15.
According to reports, the FDA lowered the duration for booster doses from at least six months after the initial series to at least five months for everyone aged 12 and up on Monday. In individuals aged 12 to 15, the agency has judged that the protective health benefits of a single booster dose of the Pfizer-BioNTech Covid-19 vaccine to give sustained protection against the virus and its catastrophic consequences exceed the potential hazards.
The FDA stated it found "no new safety concerns" following a booster shot in young teenagers, and that there were no new complaints of myocarditis or pericarditis, two types of heart inflammation connected to boosters.
The decision was made as the Omicron variant spreads fast across the United States, resulting in record-high hospitalizations among children and teenagers.
White House announces plan aimed at boosting competition in US meat, poultry
US reports more than 1 million new COVID-19 cases
Biden to cut meat prices, virtual meet with farmers